Navigation Links
ThromboGenics Announces Business Update and 2008 Full Year Results
Date:3/12/2009

s compares to EUR 40.1 million in cash and EUR 6.7 million in short term investments at December 31, 2007. This level of cash resources is expected to allow ThromboGenics to drive forward its operational plans for the next two years.

Patrik De Haes, CEO of ThromboGenics, commenting on today's announcement, said: "ThromboGenics had a very successful 2008, making excellent progress with its development pipeline and reporting a pre-tax profit for the period. The recent start of our Phase III program with microplasmin in patients with back of the eye disease is a major milestone for the Company. Our decision to initiate this pivotal clinical program was driven by the excellent clinical Phase II data that we have generated, combined with our strong financial position. This is the result of the EUR30m upfront payment we received as part of our major strategic licensing deal for TB-403 with Roche, signed in June 2008. We are also making good progress with TB-402, a novel long acting anti-coagulant which we believe has advantages over currently marketed products. As ThromboGenics continues to transform itself into a late-stage development company, I am confident that we have all the tools needed to ensure our corporate success."

For the full report of these results please go to http://www.thrombogenics.com

About ThromboGenics

ThromboGenics is a biotechnology company focused on the discovery and development of biopharmaceuticals for the treatment of eye disease, vascular disease and cancer. The Company's lead product Microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal indications and as a potential therapy for stroke. ThromboGenics is also developing novel antibody
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
2. ThromboGenics N.V.: Business Update
3. ThromboGenics Announces Half Year Results 2008
4. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
5. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
6. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
7. ThromboGenics N.V. - Business Update
8. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
9. ThromboGenics Announces 2007 Full Year Results
10. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
11. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... (PRWEB) January 14, 2014 iLab Solutions, the ... as the new Director of Product Strategy. In this role, ... as iLab sub-teams to guide in the development of iLab ... provides the maximum possible benefit to the scientific community by ...
(Date:1/14/2014)... MD (PRWEB) January 14, 2014 ... to developing innovative information technology solutions for patients, ... health care stakeholders, announced today the signing of ... US Food and Drug Administration (FDA). This ...
(Date:1/14/2014)... Orange, CA (PRWEB) January 14, 2014 Kerr ... a 10-minute video and additional how-to information about dual arch ... Great Restorations with Dual Arch Impressions,” the blog entry serves ... the technique and houses a step-by-step demonstration by Dr. David ...
(Date:1/14/2014)... BioMedomics, Inc. , a Point of Care ... novel disease specific POC tests, announced today that it has ... of $690,000. The investment is from private investors and is ... of private investors has significant successful experience in early investments ...
Breaking Biology Technology:iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2BioMedomics, Inc. Closes $690K Round of Financing 2
... AMSTERDAM, August 17 SynCo ... Inc. today,announced a strategic partnership to produce Versartis, lead ... to treat type 2 diabetes,Under the agreement, SynCo will ... optimize the manufacturing process to,increase yields for the forthcoming ...
... /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc.,(Nasdaq: CHBT ) ("China-Biotics", "the ... marketing and,distribution of probiotics products, today announced its financial results ... 30, 2009. , , First Quarter 2010 ... to $15.4 million, -- Gross profit rose ...
... water for granted, that ordinary tap water could become deadly ... School of Physics and Astronomy. To combat the threat ... the physicist has developed a new system to monitor the ... time. Modifying special fibers developed in his Tel ...
Cached Biology Technology:SynCo Bio Partners to Manufacture Versartis Novel Drug for Type 2 Diabetes 2China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 2China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 3China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 4China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 5China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 6China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 7China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 8China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 9China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 10China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 11Monitoring water through a snake's eyes 2Monitoring water through a snake's eyes 3
(Date:7/9/2014)... of studies suggest that children delivered by Caesarean section have ... But it is still unknown why this is the case ... the Faculty of Health and Medical Sciences therefore decided to ... immune system in a study of newborn mouse pups. ... Caesarean section had developed a lower number of cells that ...
(Date:7/9/2014)... switch out one gene for another in a line ... fiction to reality within this decade. As with any ... of fixing disease-causing genes in humans, for example--as well ... put one of those concerns to rest: using gene-editing ... of mutations in the cells. The new results were ...
(Date:7/9/2014)... Ind. - Regulated deer hunts in Indiana state parks ... decades of damage caused by overabundant populations of white-tailed ... led by Michael Jenkins, associate professor of forest ecology, ... policy of organizing hunts in state parks has successfully ... wildflowers rendered scarce by browsing deer. , Jenkins ...
Breaking Biology News(10 mins):Mouse study: Natural birth may strengthen the immune system 2No extra mutations in modified stem cells, study finds 2No extra mutations in modified stem cells, study finds 3Hunting gives deer-damaged forests in state parks a shot at recovery 2
... 2013 AT&T * and NEC Corporation of ... workhorse among ruggedized 4G LTE smartphones , the ... equipped with AT&T Enhanced Push-to-Talk (EPTT)**, NEC ... is aimed at breaking productivity barriers to keep workforces ...
... anabolic agent for tissue-building and energy storage, promoting the ... inhibiting their breakdown and release into the circulatory system. ... entry into muscle tissue, where the glucose is metabolized ... exist in understanding the precise molecular mechanisms by which ...
... YORK , June 19, 2013  New York College of ... States Patent and Trademark Office for detecting biometric changes through ... have been injured, attacked or killed. This patent ... Agreements of New York College of Health Professions. ...
Cached Biology News:AT&T and NEC Introduce Ultra-Rugged Smartphone Designed for Hard Work, Real Life 2AT&T and NEC Introduce Ultra-Rugged Smartphone Designed for Hard Work, Real Life 3AT&T and NEC Introduce Ultra-Rugged Smartphone Designed for Hard Work, Real Life 4AT&T and NEC Introduce Ultra-Rugged Smartphone Designed for Hard Work, Real Life 5Breakthrough research of essential molecule reveals important targets in diabetes and obesity 2New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 2New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 3New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 4
Rb anti-Occludin (C-term GST)...
anti-JNK2 Immunogen: Recombinant human JNK2 protein Accession Number: NM_002752 Quality Assurance: Routinely evaluated by immunoblot. Molecular Weight: 46 and/or 54 kDa Available ...
...
Prepared with distilled water. Yeast extract solution is autolyzed at 150 g/L....
Biology Products: